Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.

Blood cancer journal - 15 May 2019

Shea Lauren K, Honjo Kazuhito, Redden David T, Tabengwa Edlue, Li Ran, Li Fu-Jun, Shakhmatov Mikhail, Chiorazzi Nicholas, Davis Randall S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Heavy Chains

Share to Immunophenotyping

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Prognosis

Share to Receptors, Cell Surface

Source

Open in PubMed Open full text

Identifiers

PMID: 31092813
DOI: 10.1038/s41408-019-0207-7
PMCID: PMC6520396

Genes

FCRL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status.PMID 31092813Read ↗

FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.Semantic proximity Read ↗

FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.Semantic proximity Read ↗

Prognostic factors and risk stratification in chronic lymphocytic leukemia.Semantic proximity Read ↗

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV geneSemantic proximity Read ↗

FCRL1 immunoregulation in B cell development and malignancySemantic proximity Read ↗

Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL.Semantic proximity Read ↗

Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseasesSemantic proximity Read ↗

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.Semantic proximity Read ↗

Prognostic markers in chronic lymphocytic leukemia: a comprehensive review.Semantic proximity Read ↗

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B‐cell chronic lymphocytic leukemiaSemantic proximity Read ↗

Roles for the FCRL6 Immunoreceptor in Tumor ImmunologySemantic proximity Read ↗

CLL biology and prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.